Biotechnology: Alternatives to human plasma-derived therapeutic proteins

Best Practice and Research: Clinical Haematology

Volumn 13, Issue 4, 2000, Pages 669-688

  Lynch, Thomas J ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

Biotechnology; Blood proteins; Gene expression; Gene therapy; Human; Protein engineering; Recombinant proteins; Transgenes; Transgenics

Indexed keywords

ALBUMIN; AMINO ACID; ASPARTIC ACID DERIVATIVE; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8A; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9A; COMPLEMENTARY DNA; GLUTAMIC ACID DERIVATIVE; GLYCAN DERIVATIVE; GLYCOPROTEIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; MONOCLONAL ANTIBODY; NATURAL PRODUCT; PLASMA PROTEIN; POLYPEPTIDE; PROTEIN DERIVATIVE; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; RECOMBINANT DNA; RECOMBINANT PROTEIN; SERINE DERIVATIVE; THROMBIN; TYROSINE DERIVATIVE; UNINDEXED DRUG; VON WILLEBRAND FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOTECHNOLOGY; CHO CELL; COMMERCIAL PHENOMENA; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG SYNTHESIS; GENE THERAPY; GENETIC ENGINEERING; HEALTH CARE AVAILABILITY; HEALTH CARE COST; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; PLASMA; PRIORITY JOURNAL; TRANSGENIC ANIMAL; TRANSGENIC PLANT;

EID: 0034520683     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1053/beha.2000.0100     Document Type: Article

References (136)

1. Expression and structure-function properties of recombinant factor VIII
2. The manufacturing of the recombinant factor VIII, Kogenate
3. Design and operation of a recombinant mammalian cell manufacturing process for rFVIII
4. Recombinate: Viral safety and final product manufacturing testing and specifications
5. Cell culture and purification process - Purity and safety testing
6. Summary of clinical experience with recombinant factor VIII products - Recombinate
7. Summary of clinical experience with recombinant factor VIII products - Kogenate
8. Preclinical and in vitro studies of recombinant factor VIII
9. In-process controls and characterization of recombinate antihemophilic factor (recombinant)
10. Experiences with recombinant factor VIII products: Development of inhibitors and immune tolerance therapy
11. Incidence of inhibitors in haemophilia A patients - A review of recent studies of recombinant and plasma-derived factor VIII concentrates
12. Human recombinant DNA-derived antihaemophilic factor (factor VIII) in the treatment of haemophilia A: Conclusions of a 5-year study of home therapy
13. A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A
14. Frequent but low titre factor VIII inhibitors in haemophilia A patients treated with high purity concentrates
15. Recombinant factor IX
16. Biochemical characterization of recombinant factor IX
17. Biochemistry of factor IX and molecular biology of hemophilia B
18. Expression, purification, and characterization of recombinant gamma-carboxylated factor IX synthesized in Chinese hamster ovary cells
19. The manufacturing process for recombinant factor IX
20. Gamma-carboxyglutamic acids 36 and 40 do not contribute to human factor IX function
21. Clinical evaluation of recombinant factor IX
22. Structure, biology, and genetics of von Willebrand factor
23. In vitro evaluation of the haemostatic value of the LFB-von Willebrand concentrate
24. Biological effects of a S/D-treated, very high purity, von Willebrand factor concentrate in five patients with severe von Willebrand disease
25. Plasma product treatment in various types of von Willebrand's disease
26. Production of highly homogeneous and structurally intact recombinant von Willebrand factor multimers by furin-mediated propeptide removal in vitro
27. Recombinant von Willebrand factor
28. In vivo characterization of recombinant von Willebrand factor in dogs with von Willebrand disease
29. Effects of human recombinant, plasma-derived and porcine von Willebrand factor in pigs with severe von Willebrand disease
30. Other clotting factor deficiencies
31. Antithrombin III: Physiology, deficiency, and replacement therapy
32. Characterization of recombinant human antithrombin III synthesized in Chinese hamster ovary cells
33. Heterogeneity of recombinant human antithrombin III expressed in baby hamster kidney cells. Effect of glycosylation differences on heparin binding and structure
34. Effect of individual carbohydrate chains of recombinant antithrombin on heparin affinity and on the generation of glycoforms differing in heparin affinity
35. Alpha I-antitrypsin deficiency
36. Biochemical efficacy and safety of monthly augmentation therapy for alpha I-antitrypsin deficiency
37. High-level production of fully active human alpha I-antitrypsin in Escherichia coli
38. Glycosylation of human alpha I-antitrypsin in Saccharomyces cerevisiae and methylotrophic yeasts
39. Recombinant DNA-produced alpha I-antitrypsin administered by aerosol augments lower respiratory tract antineutrophil elastase defenses in individuals with alpha I-antitrypsin deficiency
40. Production of recombinant human serum albumin from Saccharomyces cerevisiae
41. The development of recombinant human serum albumin
42. Comparative studies of recombinant human albumin and human serum albumin derived by blood fractionation
43. Complete determination of disulfide forms of purified recombinant human serum albumin, secreted by the yeast Pichia pastoris
44. Physicochemical and immunochemical properties of recombinant human serum albumin from Pichia pastoris
45. Safety of human albumin as a constituent of biologic therapeutic products
46. The epidemiology of virus transmission by plasma derivatives: Clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type I
47. Construction and characterization of an active factor VIII variant lacking the central one-third of the molecule
48. A large region (approximately equal to 95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity
49. Novel forms of B-domain-deleted recombinant factor VIII molecules. Construction and biochemical characterization
50. Development of freeze-dried albumin-free formulation of recombinant factor VIII SQ
51. Recombinant clotting factors in the treatment of hemophilia
52. Recombinant, B-domain deleted factor VIII (r-VIII SQ): Pharmacokinetics and initial safety aspects in hemophilia A patients
53. The treatment of factor VIII inhibitors - A general overview
54. Inhibitors in congenital haemophilia
55. Acquired haemophilia
56. Autoimmune factor VIII inhibitors
57. The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience
58. Use of porcine factor VIII in the treatment of patients with acquired hemophilia
59. Activated factor VII activates factors IX and X on the surface of activated platelets: Thoughts on the mechanism of action of high-dose activated factor VII
60. Clinical experience with human plasma-derived factor Vlla in patients with hemophilia A and high titer inhibitors
61. Characterization of a rDNA coding for human factor VII
62. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa
63. Recombinant factor VIIa. (NovoSeven) in the treatment of internal bleeding in patients with factor VIII and IX inhibitors
64. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery
65. Feasibility of using recombinant factor VIIa in continuous infusion
66. Management of an anti-factor VIII inhibitor occurring during surgical procedure with continuous fusion of Novoseven
67. Can we improve on nature? 'Super molecules' of factor VIII
68. Enhanced thrombin sensitivity of a factor VIII-heparin cofactor II hybrid
69. Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa
70. Mild hemophilia A caused by increased rate of factor VIII A2 subunit dissociation: Evidence for nonproteolytic inactivation of factor VIIIa in vivo
71. Mutation at either Arg336 or Arg 562 in factor VIII is insufficient for complete resistance to activated protein C(APC)-mediated inactivation: Implications for the APC resistance test
72. Replacing the first epidermal growth factor-like domain of factor IX with that of factor VII enhances activity in vitro and in canine hemophilia B
73. 'Normal' thrombin generation
74. The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies
75. Characterization of factor VIII B-cell inhibitor epitopes
76. Immunoblot crossreactivity of factor VIII inhibitors with porcine factor VIII
77. Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules
78. Production of therapeutic proteins in the milk of transgenic livestock
79. Production of goats by somatic cell nuclear transfer
80. Transgenic livestock as bioreactors: Stable expression of human alpha I-antitrypsin by a flock of sheep
81. Blood proteins from transgenic animal bioreactors
82. Expression of human anti-hemophilic factor IX in the milk of transgenic sheep
83. High level expression of active human alpha-I-antitrypsin in the milk of transgenic sheep
84. Production of functional human alpha I-antitrypsin by plant cell culture
85. Transgenically produced human antithrombin: Structural and functional comparison to human plasma-derived antithrombin
86. Transgenic pigs produce functional human factor VIII in milk
87. Expression of human blood clotting factor VIII in the mammary gland of transgenic sheep
88. Vitamin K-dependent protein production in transgenic animals
89. High-level expression of a heterologous protein in the milk of transgenic swine using the cDNA encoding human protein C
90. Proteolytic processing of human protein C in swine mammary gland
91. Proteolytic maturation of protein C upon engineering the mouse mammary gland to express furin
92. Haemophilia A gene therapy
93. Gene therapy for the hemophilias
94. Gene therapy for hemophilia A
95. Advances toward gene therapy for hemophilia at the millennium
96. Gene therapy for the hemophilias
97. Sustained secretion of human alpha-I-antitrypsin from murine muscle transduced with adeno-associated virus vectors
98. Differentiation-specific enhancer activity in transduced keratinocytes: A model for epidermal gene therapy
99. Expression of human alpha I antitrypsin in murine hematopoietic cells in vivo after retrovirus-mediated gene transfer
100. Bone marrow stromal cells as targets for gene therapy of hemophilia A
101. Bone marrow stromal cell-mediated gene therapy for hemophilia A: In vitro expression of human factor VIII with high biological activity requires the inclusion of the proteolytic site at amino acid 1648
102. Sustained expression of high levels of human factor IX from human cells implanted within an immunoisolation device into athymic rodents
103. Ex vivo fibroblast transduction in rabbits results in long-term (>600 days) factor IX expression in a small percentage of animals
104. Persistent delivery of factor IX in mice: Gene therapy for hemophilia using implantable microcapsules
105. Stabilized plasmid-lipid particles: Construction and characterization
106. Development and application of adenoviral vectors for gene therapy of cancer
107. Development and application of a minimal-adenoviral vector system for gene therapy of hemophilia A
108. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: Tolerization of factor IX and vector antigens allows for long-term expression
109. Hepatic gene therapy for haemophilia B
110. Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: Implications for gene therapy
111. Effects of macrophage depletion and anti-CD40 ligand on transgene expression and redosing with recombinant adenovirus
112. Inhibition of NF-kappaB activation in combination with bcl-2 expression allows for persistence of first-generation adenovirus vectors in the mouse liver
113. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity
114. Sustained high-level expression of full-length human-factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector
115. Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy
116. Evaluation of an adenoviral vector encoding full-length human factor VIII in hemophiliac mice
117. In vivo evaluation of an adenoviral vector encoding canine factor VIII: High-level, sustained expression in hemophiliac mice
118. In vivo hepatic gene therapy: Complete albeit transient correction of factor IX deficiency in hemophilia B dogs
119. Adeno-associated viral vector-mediated gene transfer of human blood coagulation factor IX into mouse liver
120. Sustained correction of bleeding disorder in hemophilia B mice by gene therapy
121. Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia
122. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector
123. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors
124. Adeno-associated virus as a vector for liver-directed gene therapy
125. Human factor VIII can be packaged and functionally expressed in an adeno-associated virus background: Applicability to haemophilia A gene therapy
126. Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII-deficient mice
127. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors
128. Biosynthesis, assembly and secretion of coagulation factor VIII
129. Factors impeding efficient expression of factor VIII complementary DNA minigenes
130. Optimization of the human factor VIII complementary DNA expression plasmid for gene therapy of hemophilia A
131. The three in-frame ATG, clustered in the translation initiation sequence of human factor IX gene, are required for an optimal protein production
132. Efficient adenoviral vector transduction and expression of functional human factor VIII in cultured primary human hepatocytes
133. Germline alteration by gene therapy: Assessing and reducing the risks
134. A noval SV40-based vector successfully transduces and expresses an alpha I-antitrypsin ribozyme in a human hepatoma-derived cell line
135. Ribozyme-associated specific gene replacement of the alpha I-antitrypsin gene in human hepatoma cells
136. In vivo site-directed mutagenesis of the factor IX gene by chimeric RNA/DNA oligonucleotides